These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 18421052

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH.
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M.
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ, Goodin S.
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risks and benefits associated with novel phase 1 oncology trial designs.
    Koyfman SA, Agrawal M, Garrett-Mayer E, Krohmal B, Wolf E, Emanuel EJ, Gross CP.
    Cancer; 2007 Sep 01; 110(5):1115-24. PubMed ID: 17628485
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. End points in cancer clinical trials and the drug approval process.
    Schilsky RL.
    Clin Cancer Res; 2002 Apr 01; 8(4):935-8. PubMed ID: 11948095
    [Abstract] [Full Text] [Related]

  • 14. Novel agents in the treatment of metastatic colorectal cancer.
    Leong S, Messersmith WA, Tan AC, Eckhardt SG.
    Cancer J; 2010 Apr 01; 16(3):273-82. PubMed ID: 20526106
    [Abstract] [Full Text] [Related]

  • 15. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G, Cancer Vaccine Clinical Trial Working Group.
    J Immunother; 2007 Jan 01; 30(1):1-15. PubMed ID: 17198079
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):636-44. PubMed ID: 21422403
    [Abstract] [Full Text] [Related]

  • 18. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM, Boerner SA, Seymour L.
    Clin Cancer Res; 2010 Mar 15; 16(6):1710-8. PubMed ID: 20215546
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.